IDEAYA Biosciences Inc IDYA

Healthcare Biotechnology

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.

NDAQ:IDYA - Post by User

IDEAYA Biosciences Inc

<< Previous

Bullboard Posts

Next >>

(301)
•••

Post by whytestockson Jul 08, 2024 10:47am

40 Views

Post# 36122693

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expans

BREAKING NEWS: $IDYA IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung CancerIDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer PR Newswire ~39% Overall Response Rate ( ORR ): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out...IDYA - IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer

<< Previous

Bullboard Posts

Next >>

High Tide acquires German pharma wholesaler Purecan